60 Degrees Pharmaceuticals, Inc. (SXTP) AI Stock Analysis

• Market Cap: $3.21M
• Dividend Yield: N/A
• Average Volume (3M): 199.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.05
• Revenue Growth: 192.72%
• EPS Growth: 83.61%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.67
• Shares Outstanding: 4,230,448
• 10 Day Avg. Volume: 488,900
• 30 Day Avg. Volume: 199,179
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.73
• Price to Sales (P/S): 4.83
• P/FCF Ratio: -0.50
• Enterprise Value/Market Cap: 3.48
• Enterprise Value/Revenue: 11.59
• Enterprise Value/Gross Profit: 60.52
• Enterprise Value/Ebitda: -1.41
• 1Y Price Target: $4.40
• Price Target Upside: 478.95% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: $0.83 ▲(9.21% Upside)

SXTP's overall stock score is primarily impacted by its weak financial performance and valuation metrics. The technical analysis also indicates bearish momentum. The lack of earnings call insights and corporate events means these factors do not influence the score.

Positive Factors

Market Expansion

The expansion of sales and marketing initiatives suggests increased market demand and potential revenue growth, strengthening the company's market position.

FDA Engagement

Engagement with the FDA and potential Breakthrough Therapy Designation could enhance product credibility and accelerate regulatory approval processes.

Equity Improvement

Improved equity position enhances financial stability and provides a stronger foundation for future growth and investment opportunities.

Negative Factors

Negative Cash Flow

Persistent negative cash flow can hinder operational flexibility and necessitate reliance on external funding, impacting long-term sustainability.

Declining Revenues

Declining revenues reflect challenges in market penetration and product adoption, potentially affecting long-term growth prospects.

Profitability Issues

Consistent unprofitability raises concerns about the company's ability to achieve sustainable financial performance and long-term viability.

60 Degrees Pharmaceuticals, Inc. Business Overview & Revenue Model

Company Description

60 Degrees Pharmaceuticals, Inc. (SXTP) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of infectious diseases. The company operates primarily in the healthcare sector, specializing in drug development aimed at addressing unmet medical needs. Its core products include novel pharmaceutical formulations and delivery systems designed to improve patient outcomes in the management of various infectious diseases.

How the Company Makes Money

60 Degrees Pharmaceuticals generates revenue through the commercialization of its pharmaceutical products, which may include direct sales to healthcare providers and distribution partnerships with pharmaceutical distributors. The company may also derive income from licensing agreements and collaborations with other biopharmaceutical companies, leveraging its research and development capabilities to create valuable intellectual property. Additionally, government grants and funding from research institutions may contribute to its earnings as the company advances its drug development pipeline.

60 Degrees Pharmaceuticals, Inc. Financial Statement Overview

Summary

The company is facing significant financial challenges, with declining revenues, persistent losses, and negative cash flow. Despite some recent improvements in equity and reduced debt, profitability and cash generation remain critical issues.

Income Statement

The company has been experiencing declining revenues, with a significant drop in total revenue from 2020 to 2023. Gross profit margin has been negative in recent years, indicating cost management issues. Net profit margin has been consistently negative, reflecting ongoing unprofitability. Despite some revenue growth in 2024, profitability remains a major concern.

Balance Sheet

The debt-to-equity ratio improved significantly from previous years due to reduced total liabilities, but the company still has challenges with negative equity in past years. In 2024, equity became positive, which is a positive sign. The equity ratio indicates a relatively higher reliance on equity compared to previous years.

Cash Flow

The company has struggled with negative operating cash flow in recent years, indicating challenges with cash generation from core operations. Free cash flow has also been negative, reflecting ongoing investment and financing needs. Positive financing cash flows suggest reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	963.53K	607.57K	253.57K	223.21K	1.16M	2.18M
Gross Profit	184.44K	222.81K	-220.98K	-209.16K	309.60K	1.48M
EBITDA	-7.90M	-7.88M	-1.43M	-2.11M	-1.01M	-341.17K
Net Income	-7.98M	-7.95M	-3.77M	-6.18M	-4.25M	-3.03M
Balance Sheet
Total Assets	6.69M	5.76M	7.78M	1.30M	1.39M	2.61M
Cash, Cash Equivalents and Short-Term Investments	4.12M	3.39M	2.14M	264.87K	115.40K	191.70K
Total Debt	153.76K	155.89K	172.67K	22.42M	18.80M	15.92M
Total Liabilities	2.34M	1.80M	2.99M	25.45M	19.55M	20.68M
Stockholders Equity	4.43M	4.04M	4.87M	-23.58M	-17.58M	-17.50M
Cash Flow
Free Cash Flow	-6.86M	-5.83M	-4.66M	-1.07M	-684.50K	-238.28K
Operating Cash Flow	-6.79M	-5.65M	-4.54M	-1.01M	-649.11K	-167.30K
Investing Cash Flow	1.62M	-1.89M	-115.89K	-60.13K	-35.39K	-70.98K
Financing Cash Flow	5.98M	7.05M	6.47M	1.22M	611.23K	277.36K

60 Degrees Pharmaceuticals, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SXTP, the sentiment is Negative. The current price of 0.76 is below the 20-day moving average (MA) of 0.94, below the 50-day MA of 1.18, and below the 200-day MA of 1.77, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 24.32 is Positive, neither overbought nor oversold. The STOCH value of 19.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SXTP.

60 Degrees Pharmaceuticals, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SXTP	40 Underperform	$3.21M	-0.10	-152.19%	―	192.72%	83.61%
ONCO	33 Underperform	$2.75M	>-0.01	-263.57%	―	-34.58%	96.41%
KALA	31 Underperform	$6.68M	-0.10	―	―	―	52.39%
OGEN	29 Underperform	$3.66M	-0.05	-168.95%	―	―	90.27%

60 Degrees Pharmaceuticals, Inc. Corporate Events

60 Degrees Pharmaceuticals Holds Annual Stockholders Meeting

On October 8, 2025, 60 Degrees Pharmaceuticals, Inc. held its virtual 2025 Annual Stockholders Meeting, where various proposals were voted on by the shareholders. The meeting saw the election of five directors, approval of an amendment to increase shares in the 2022 Equity Incentive Plan, a reverse stock split, and the ratification of RBSM LLP as the accounting firm for 2025, all of which were approved.